NeuroSense enters binding term sheet to advance PrimeC for ALS

NeuroSense (NRSN) Therapeutics announced that it has entered into a binding term sheet with a leading global pharmaceutical company to advance the development and commercialization of PrimeC, its proprietary treatment drug for amyotrophic lateral sclerosis in certain key territories. NeuroSense would retain full rights to PrimeC in other key territories. The binding term sheet outlines substantial financial terms from the pharmaceutical company, including: A substantial upfront payment upon signing a definitive agreement; Funding for the Phase 3 clinical trial; Regulatory and net sales milestone payments; and A tiered royalty structure reaching double-digit percentage on annual net sales. The binding term sheet is subject to finalization of a definitive agreement, anticipated in the first quarter of 2025. The pharmaceutical company would have an exclusive license to distribute, market, promote, sell and develop PrimeC for ALS in certain key markets, and non-exclusive rights for research and manufacturing for PrimeC for ALS, subject to terms and conditions in the definitive agreement.

Don't Miss Our Christmas Offers:

• Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
• Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on NRSN:

• NeuroSense Advances ALS Treatment with PrimeC, Boosts Financial Position
• NeuroSense reports first nine months EPS (48c) vs. (55c) last year
• NeuroSense Therapeutics Regains Nasdaq Compliance
• NeuroSense cut to Hold at Maxim following PrimeC FDA feedback
• NeuroSense downgraded to Hold from Buy at Maxim